Allos Therapeutics to Report 2007 Second Quarter Financial Results on August 7, 2007
18 Julho 2007 - 9:00AM
PR Newswire (US)
WESTMINSTER, Colo., July 18 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH) today announced that it will
report 2007 second quarter financial results on Tuesday, August 7,
2007, before the U.S. financial markets open. Paul L. Berns,
President and Chief Executive Officer, and other members of Allos'
senior management will provide a company update and discuss results
via web cast and conference call on Tuesday, August 7, 2007 at 8:30
AM ET. The web cast of this call will be available from the
homepage and the investors/media section of the Company's web site,
http://www.allos.com/, and will be archived for 30 days.
Alternatively, callers may participate in the conference call by
dialing 866-225-8729 (domestic) or 480-629-9564 (international).
Web cast and telephone replays of the conference call will be
available approximately two hours after the completion of the call
through Friday, August 24, 2007. Callers can access the replay by
dialing 303-406-7325 (domestic) or 800-590- 3030 (international).
The passcode is 3761474. About Allos Therapeutics Allos
Therapeutics, Inc. (ALTH) is a biopharmaceutical company focused on
the development and commercialization of small molecule
therapeutics for the treatment of cancer. The Company's lead
product candidate, PDX (pralatrexate), is a novel antifolate
currently under evaluation in a pivotal Phase 2 trial in patients
with relapsed or refractory peripheral T-cell lymphoma. The Company
is also investigating PDX in patients with non small cell lung
cancer and a range of other lymphoma sub-types. The Company's other
product candidate is RH1, a targeted chemotherapeutic agent for
which the Company expects to initiate a Phase 1 study in patients
with advanced solid tumors in the second half of 2007. For
additional information, please visit the Company's website at
http://www.allos.com/. Safe Harbor Statement The 2007 second
quarter results press release and conference call will contain
forward-looking statements that involve significant risks and
uncertainties, including those that can be found in the "Risk
Factors" section of Allos' Form 10-K for the year ended December
31, 2006 and in Allos' periodic reports on Form 10-Q and Form 8-K.
Allos is providing the information contained in the press release
and conference call as of the date of the release and does not
undertake any obligation to update any forward-looking statements
as a result of new information, future events or otherwise. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in the press release or the
conference call. No forward- looking statement can be guaranteed
and actual events and results may differ materially from those
projected. DATASOURCE: Allos Therapeutics, Inc. CONTACT: Derek
Cole, Vice President, Investor Relations, +1-720-540- 5367, , or
Jennifer Neiman, Senior Manager, Corporate Communications,
+1-720-540-5227, , both of Allos Therapeutics, Inc. Web site:
http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Allos Therapeutics, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Allos Therapeutics (MM)